Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its platform approach and GlycoTarget database in a poster presentation at the 2024 American Association for Cancer Research (AACR) Meeting, being held in San Diego, California, United States, between 05-10 April 2024.

Glycotope将在2024年4月8日于德国柏林举行的2024年AACR会议上介绍开发抗糖靶抗体的平台方法–Glycotope GmbH是一家利用专有平台技术开发针对携带肿瘤特异性碳水化合物结构的蛋白质的抗体的生物技术公司，今天宣布将在2024年4月5日至10日于美国加利福尼亚州圣地亚哥举行的2024年美国癌症研究协会（AACR）会议上以海报形式展示其平台方法和Glycottarget数据库。

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: “At Glycotope, we have established a standardized process for the data collection and prioritization of potential protein/carbohydrate combined glycoepitopes (GlycoTargets). We look forward to attending AACR to present our workflow and corresponding database to leading cancer research experts, illustrating how this information is subsequently used for the targeted discovery of antibodies that bind to our GlycoTargets, offering increased tumor-specificity compared to simple protein targets.” Poster details are as follows: Abstract: Download here  Title: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms Abstract Number: 5896 Link Session Date and Time: Tuesday Apr 09, 2023 1:30 PM – 05:00 PM PDT Location: Poster Section 25, Poster Board Number 10 Contact Information: Glycotope GmbH Dr.

Glycotope GmbH首席科学官帕特里克·凯勒（Patrik Kehler）评论道：“在Glycotope，我们已经建立了一个标准化的过程，用于数据收集和优先排序潜在的蛋白质/碳水化合物结合糖表位（糖靶）。我们期待着参加AACR，向领先的癌症研究专家介绍我们的工作流程和相应的数据库，说明这些信息随后如何用于靶向发现与我们的糖靶结合的抗体，与简单的蛋白质靶点相比，提供了更高的肿瘤特异性。”海报详细信息如下：摘要：下载此处标题：开发特异性识别癌症相关糖型抗体的平台方法摘要编号：5896链接会议日期和时间：2023年4月9日星期二下午1:30–05:00 PDT地点：海报第25节，海报板编号10联系信息：Glycotope GmbH Dr。

Patrik Kehler (CSO) Phone: +49 30 9489 2600 Email: contact@glycotope.com About Glycotope Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydr.

帕特里克·凯勒（CSO）电话：+49 30 9489 2600电子邮件：contact@glycotope.com关于Glycotope Glycotope是一家生物技术公司，利用专有技术平台开发独特的肿瘤特异性单克隆抗体。我们的抗体靶向特定的肿瘤相关碳水化合物结构或蛋白质/碳水化合物。